Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD (RAND-CFR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ron Blankstein, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01754259
First received: December 12, 2012
Last updated: August 25, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)